⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 9, 2024Neurology

Longer-term Safety and Efficacy of Ofatumumab in People with Relapsing Multiple Sclerosis for Up to 6 Years (P9-6.010)

Heinz Wiendl Stephen L. Hauser Jacqueline Nicholas de Sèze Sven G. Meuth Paul S. Giacomini Derrick Robertson Sibyl Wray Alit Bhatt Xixi Hu Haoyi Fu Valentine Jehl Roseanne Sullivan Ibolya Boer Jeffrey A. Cohen Ludwig Kappos

View Full Paper

Ask AI

Bookmark

Share

Abstract

To assess ofatumumab's longer-term safety and efficacy for up to 6 years in people with relapsing multiple sclerosis (pwRMS).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wiendl et al. (2024) studied this question.

synapsesocial.com/papers/68e6fcb5b6db643587676ecc https://doi.org/10.1212/wnl.0000000000205570

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Longer-term (Up to 6 Years) Efficacy of Ofatumumab in People with Recently Diagnosed and Treatment-naive Relapsing Multiple Sclerosis (S31.003)2024 · 4 citations
2Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosiscohort · 2025 · 7 citations
3Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extensioncohort · 2023 · 56 citations
4Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosisRCT · 2014 · 278 citations
5Real-world effectiveness and safety of ofatumumab in multiple sclerosis: a longitudinal study integrating clinical, cognitive, and MRI outcomescohort · 2026